Canada-based dermatology specialist Crescita Therapeutics (TSX: CTX) has entered into a development and commercialization license agreement with the Canadian subsidiary of Taro Pharmaceutical Industries (NYSE:TARO).
Under the terms of the accord, Crescita has granted Taro an exclusive license to the rights to sell and distribute Pliaglis (lidocaine and tetracaine) in the US market and for a second-generation enhanced version with patent pending (the Enhanced Formulation).
In consideration of the rights granted under the Agreement, Taro will make the following payments to Crescita:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze